➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
McKinsey
Harvard Business School
Boehringer Ingelheim
Johnson and Johnson
McKesson

Last Updated: July 26, 2021

DrugPatentWatch Database Preview

Pfizer Company Profile


Email this page to a colleague

« Back to Dashboard

Summary for Pfizer

Drugs and US Patents for Pfizer

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer MINIPRESS XL prazosin hydrochloride TABLET, EXTENDED RELEASE;ORAL 019775-001 Jan 29, 1992 DISCN No No ⤷  Free Forever Trial ⤷  Free Forever Trial
Pfizer SINEQUAN doxepin hydrochloride CAPSULE;ORAL 016798-005 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial
Pfizer DAURISMO glasdegib maleate TABLET;ORAL 210656-001 Nov 21, 2018 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial
Pfizer DAURISMO glasdegib maleate TABLET;ORAL 210656-001 Nov 21, 2018 RX Yes No 10,414,748 ⤷  Free Forever Trial Y Y ⤷  Free Forever Trial
Pfizer PFIZERPEN G penicillin g potassium TABLET;ORAL 060075-003 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Free Forever Trial ⤷  Free Forever Trial
Pfizer PFIZERPEN G penicillin g potassium TABLET;ORAL 060075-004 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Free Forever Trial ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Pfizer

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer MICRONASE glyburide TABLET;ORAL 017498-003 May 1, 1984 3,507,954 ⤷  Free Forever Trial
Pfizer GLUCOTROL XL glipizide TABLET, EXTENDED RELEASE;ORAL 020329-002 Apr 26, 1994 5,082,668 ⤷  Free Forever Trial
Pfizer MINIZIDE polythiazide; prazosin hydrochloride CAPSULE;ORAL 017986-001 Approved Prior to Jan 1, 1982 3,511,836 ⤷  Free Forever Trial
Pfizer CORVERT ibutilide fumarate INJECTABLE;INJECTION 020491-001 Dec 28, 1995 5,155,268 ⤷  Free Forever Trial
Pfizer GLYNASE glyburide TABLET;ORAL 020051-002 Mar 4, 1992 3,507,961 ⤷  Free Forever Trial
Pfizer TIKOSYN dofetilide CAPSULE;ORAL 020931-001 Oct 1, 1999 4,959,366 ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for PFIZER drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Injection 2 mg/mL, 100 mL bag ➤ Subscribe 2009-12-29
➤ Subscribe Tablets 5 mg ➤ Subscribe 2016-11-07
➤ Subscribe Delayed-release Tablets 50 mg/0.2 mg ➤ Subscribe 2009-06-29
➤ Subscribe Extended-release Tablets 11 mg ➤ Subscribe 2016-11-07
➤ Subscribe Capsules 20 mg, 40 mg, 60 mg and 80 mg ➤ Subscribe 2005-02-07
➤ Subscribe Capsules 75 mg, 100 mg and 125 mg ➤ Subscribe 2019-02-04
➤ Subscribe Capsules 0.125 mg, 0.25 mg, and 0.5 mg ➤ Subscribe 2014-05-01
➤ Subscribe Tablets 600 mg ➤ Subscribe 2005-12-21
➤ Subscribe Injection 2 mg/mL, 300 mL bag ➤ Subscribe 2009-09-01
➤ Subscribe Tablets 1 g ➤ Subscribe 2005-08-23
➤ Subscribe Delayed-release Tablets 75 mg/0.2 mg ➤ Subscribe 2008-11-28
➤ Subscribe Extended-release Tablets 4 mg and 8 mg ➤ Subscribe 2012-10-31
➤ Subscribe Injection 20 mg/mL, 2 mL and 5 mL vials ➤ Subscribe 2004-07-26
➤ Subscribe Capsules 5 mg and 10 mg ➤ Subscribe 2005-06-21
➤ Subscribe For Injection 500 mg/vial ➤ Subscribe 2011-06-17
➤ Subscribe Oral Suspension 100 mg/5 mL ➤ Subscribe 2009-08-03

Supplementary Protection Certificates for Pfizer Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0454511 SPC/GB99/008 United Kingdom ⤷  Free Forever Trial PRODUCT NAME: 2-N-BUTYL-4-SPIROCYCLOPENTANE-1-((2'-(TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-2-IMIDAZOLIN-5-ONE)(GENERIC NAME IRBESARTAN) OPTIONALLY IN THE FORM OF ONE OF ITS SALTS AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/98/086/001 19981015; UK EU/1/98/086/002 19981015; UK EU/1/98/086/003 19981015; UK EU/1/98/086/004 19981015; UK EU/1/98/086/005 19981015; UK EU/1/98/086/006 19981015
1746976 2017C/027 Belgium ⤷  Free Forever Trial PRODUCT NAME: LE SEL DE SUCROSOFATE D'IRINOTECAN, PAR EXEMPLE LE SEL DE SUCROSOFATE D'IRINOTECAN INCORPORE DANS UN LIPOSOME MODIFIE PAR PEGYLATION, TEL QU'UN LIPOSOME COMPRENANT DE LA 1,2-DISTEAROYL-SN- PHOSPHATIDYLCHOLINE, DU CHOLESTEROL ET DU N- (OMEGA-METHOXY POLY (ETHYLENE GLYCOL) (POIDS MOLECULAIRE 2000) -OXYCARBONYL)-1,2-DISEEAROYLPHOSPHATIDYLETHANOLAMINE, PAR EXEMPLE DANS DES RAPPORTS MOLAIRES 3: 2: 0,015; OU COMME DEMANDE AUXILIAIRE, IRINOTECAN; AUTHORISATION NUMBER AND DATE: EU/1/16/1130 20161018
1470124 2017/009 Ireland ⤷  Free Forever Trial PRODUCT NAME: PALBOCICLIB, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, ESTER, AMIDE OR PRODRUG THEREOF; REGISTRATION NO/DATE: EU/1/16/1147/001 EU/1/16/1147/006 20161109
1666481 1790038-2 Sweden ⤷  Free Forever Trial PRODUCT NAME: TOFACITINIB, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE CITRATE SALT; REG. NO/DATE: EU/1/17/1178 20170324
0770388 PA2009004,C0770388 Lithuania ⤷  Free Forever Trial PRODUCT NAME: ESTRADIOLI VALERAS + DIENOGESTUM; NAT. REGISTRATION NO/DATE: LT/1/09/1512/001, 2009 04 06 LT/1/09/1512/002, 2009 04 06 LT/1/09/1512/003 20090406; FIRST REGISTRATION: BE 327792 20081103
1077912 07C0050 France ⤷  Free Forever Trial PRODUCT NAME: FESOTERODINE ET SES SELS AVEC DES ACIDES PHYSIOLOGIQUEMENT ACCEPTABLES NOTAMMENT L ACIDE FUMARIQUE; REGISTRATION NO/DATE IN FRANCE: EU/1/07/386/001 DU 20070420; REGISTRATION NO/DATE AT EEC: EU/1/07/386/001 DU 20070420
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Colorcon
Mallinckrodt
Baxter
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.